作者
June D Cody, Conal Daly, Marion K Campbell, Izhar Khan, Kannaiyan S Rabindranath, Luke Vale, Sheila A Wallace, Alison M MacLeod, Adrian M Grant, Susan Pennington, Ionut Nistor, Davide Bolignano, Angela C Webster
发表日期
2005
来源
Cochrane database of systematic reviews
期号
3
出版商
John Wiley & Sons, Ltd
简介
Background
Treatment with recombinant human erythropoietin (rHu EPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHu EPO use in pre‐dialysis patients which may accelerate the deterioration of renal function. However the opposing view is that if rHu EPO is as effective in pre‐dialysis patient's, improving the patients sense of well‐being may result in the onset of dialysis being delayed.
Objectives
To assess the effects of rHu EPO use in pre‐dialysis patients with renal anaemia.
引用总数
学术搜索中的文章
JD Cody, C Daly, MK Campbell, I Khan… - Cochrane database of systematic reviews, 2005